Enlivex Therapeutics earnings were -$13.1M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest ENLV earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$1.9M, down 45.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ENLV reported annual earnings of -$15.0M, with -48.3% growth.
Enlivex Therapeutics Earnings Reports & History FAQ
What were Enlivex Therapeutics's earnings last quarter?
On ENLV's earnings call on Invalid Date, Enlivex Therapeutics (NASDAQ: ENLV) reported Q2 2025 earnings per share (EPS) of -$0.08, up 50% year over year. Total ENLV earnings for the quarter were -$1.87 million. In the same quarter last year, Enlivex Therapeutics's earnings per share (EPS) was -$0.16.
Is Enlivex Therapeutics profitable or losing money?
As of the last Enlivex Therapeutics earnings report, Enlivex Therapeutics is currently losing money. Enlivex Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$13.10 million, a 41.25% decrease year over year.
What was ENLV's earnings growth in the past year?
As of Enlivex Therapeutics's earnings date in Invalid Date, Enlivex Therapeutics's earnings has grown year over year. ENLV earnings in the past year totalled -$13.10 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.